Pentabind
Pentabind use Generative AI to design aptamers that can bind to transcription factors unlike traditional drugs. They have built the largest dataset of its kind, and can design aptamers in 20x less time and cost, with 50% improved performance compared to manual experiments.
See other Drug discovery organisations
-
Enedra is harnessing the power of synthetic lethality and advanced computational Systems Biology to create therapeutics. -
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor (TCR)- based cancer immunotherapies. -
GlamorousAI is AI-first preclinical biotech focusing on the discovery of novel chemistry for challenging targets. -
Human Centric Drug Discovery helps patients with central nervous disorders by making it easier to develop drugs for their diseases.
Be part of SBC Catalyser Programme!
Spaces are limited to 10 companies per cohort. Contact Marco to get more information on our next programme in spring 2024.
Contact MarcoCopyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.